Copy For Citation
Buti M., Fung S., Gane E., Afdhal N. H., Flisiak R., GÜREL S., ...More
HEPATOLOGY INTERNATIONAL, vol.9, no.2, pp.243-250, 2015 (SCI-Expanded)
-
Publication Type:
Article / Article
-
Volume:
9
Issue:
2
-
Publication Date:
2015
-
Doi Number:
10.1007/s12072-015-9614-4
-
Journal Name:
HEPATOLOGY INTERNATIONAL
-
Journal Indexes:
Science Citation Index Expanded (SCI-EXPANDED), Scopus
-
Page Numbers:
pp.243-250
-
Keywords:
Antiviral agent, Chronic hepatitis B, Cirrhosis, Hepatitis B e antigen, Hepatitis B surface antigen, Tenofovir disoproxil, HEPATOCELLULAR-CARCINOMA, ADEFOVIR DIPIVOXIL, FOLLOW-UP, LAMIVUDINE, REGRESSION, THERAPY, DISEASE, LEVEL, RISK
-
Bursa Uludag University Affiliated:
Yes
Abstract
Phase 3 clinical studies have shown that long-term treatment with tenofovir disoproxil fumarate (TDF) can suppress hepatitis B viral load and promote significant fibrosis regression and cirrhosis reversal in a majority of treated chronic hepatitis B (CHB) patients. This retrospective analysis investigated the impact of baseline cirrhosis status on virologic, serologic, and histologic outcomes in patients treated with TDF.